

INFORMATION DISCLOSURE STATEMENT

Applicant: Merrill et al.

App. No : 10/659,711

Filed : September 11, 2003

For : ANTIBACTERIAL THERAPY WITH
BACTERIOPHAGE GENOTYPICALLY
MODIFIED BY GENETIC ENGINEERING
TO DELAY INACTIVATION BY THE
HOST DEFENSE SYSTEM

Examiner : Snyder, Stuart

Art Unit : 1648

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 6 references to be considered by the Examiner. Also enclosed are 6 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed with an RCE or before receipt of a first office action after an RCE and no fee is required.


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/15/06By: 

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Multiple sheets used when necessary)*

SHEET 1 OF 1

Application No.	10/659,711
Filing Date	September 11, 2003
First Named Inventor	Merril et al.
Art Unit	1648
Examiner	Snyder, Stuart
Attorney Docket No.	NIH298.1DC1CC1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	LAMBRIS ET AL, "Use of synthetic peptides in exploring and modifying complement reactivities" in Activators and Inhibitors of Complement, ed. R. Sim, Kluwer Academic Publishers, Boston, 1993.	
	2	Genetic Engineering News, Oct. 15, 1993, p.1.	
	3	MERRIL ET AL., "Long-circulating bacteriophage as antibacterial agents." Proc Natl Acad Sci USA 93: 3188 (1996).	
	4	VITIELLO ET AL., "An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold." Virus Res 114: 101 (2005).	
	5	ISAACS ET AL., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence." Proc Natl Acad Sci USA 89: 628 (1992).	
	6	MONTAG ET AL., "A component of the side tail fiber of Escherichia coli bacteriophage lambda can functionally replace the receptor-recognizing part of a long tail fiber protein of the unrelated bacteriophage T4." J Bacteriol 171: 4378 (1989).	

2831973
081106

Examiner Signature

Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.